Navigation Links
First Patient Enrolled in Cogentus Pharmaceuticals' Pivotal Phase 3 Trial of Novel Combination Medicine
Date:1/15/2008

Worldwide COGENT-1 Clinical Study of CGT-2168 Begins; Focus on Reducing GI

Side Effects of Antiplatelet Therapy

MENLO PARK, Calif., Jan. 15 /PRNewswire/ -- Cogentus Pharmaceuticals, Inc. today announced that the first patient has been enrolled in the company's pivotal Phase 3 study of its novel combination medicine CGT-2168. The patient entered the study at the Mobile Heart Specialists P.C. in Mobile, Ala.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071112/COGENTUSLOGO )

The study will evaluate the antiplatelet medicine CGT-2168, which is a combination of clopidogrel (currently marketed by Bristol-Myers Squibb Co. and Sanofi-Aventis as Plavix(R)) and a gastroprotectant (omeprazole) in a single pill. Developed by Cogentus, CGT-2168 is designed to provide protective cardiovascular benefits while reducing potentially serious gastrointestinal side effects commonly associated with dual antiplatelet therapy.

"This is an important milestone for Cogentus that holds promise for the millions of patients who are prescribed dual antiplatelet treatment," said Cogentus Chairman and Chief Executive Officer Mark A. Goldsmith, M.D., Ph.D. "We believe CGT-2168 has the potential to reduce significantly the gastrointestinal side effects that can cause patients to interrupt their treatment and further compromise their health status."

Antiplatelet therapy is an integral part of treating patients with acute coronary syndrome and has been shown to be effective in preventing major cardiovascular events. However, the combination of clopidogrel and aspirin is associated with gastrointestinal bleeding, which in some cases requires hospitalization and can even result in death.

The global trial is known as COGENT-1 (Clopidogrel and the Optimization of Gastrointestinal Events Trials) and is part of a clinical program expected to enroll more than 4,000 patients at hundreds of sites in the United States, Canada, Europe and South America.

Among patients who participate in the study, approximately half will receive clopidogrel and aspirin; the other half will receive CGT-2168 (clopidogrel plus omeprazole) and aspirin. Patients will be assessed regularly for any gastrointestinal side effects such as bleeding and ulcers as well as receive ongoing monitoring of their cardiovascular status.

Physicians and patients interested in obtaining more information about COGENT-1 should go to http://www.clinicaltrials.gov.

ABOUT COGENTUS

Cogentus Pharmaceuticals, Inc., of Menlo Park, CA, is a privately held specialty pharmaceutical company founded in 2006. Cogentus (http://www.cogentus.net) is committed to becoming a premier developer of innovative, fixed-dose combination prescription medicines serving unmet medical needs that drive significant commercial opportunities.

Plavix(R) is a registered trademark of Sanofi-Aventis.


'/>"/>
SOURCE Cogentus Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... Jan. 23, 2017 Laboratory Markets Limited has ... of mass spectrometry in both clinical and research laboratory ... global market size of $6.8 billion and growing to ... years, profiles the use of mass spectrometry across more ... This study investigated growth in the use of mass ...
(Date:1/23/2017)... 23, 2017 The Pharmacy Technician Certification ... of the planned 2020 accredited education requirement for ... announced in 2013 that the requirement would take ... map of program changes designed to keep pace ... pharmacy. "We have determined that ...
(Date:1/23/2017)... 23, 2017  Based on its recent analysis ... recognizes Ansell, a global leader in protection solutions, ... of the Year Award. Ansell,s comprehensive product portfolio, ... global footprint have placed it in a position ... The Company,s established product line and robust innovation ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... January 23, 2017 , ... DMG ... Innovations with Ed Begley, Jr., scheduled to broadcast Saturday, January 28, 2017 at ... was founded in 2008 to address the limitations of fatigue monitoring technologies within ...
(Date:1/23/2017)... ... 2017 , ... Wooden and plastic balance boards have been around since at least the 1950s ... is the first and only balance board to use a patent-pending design featuring high-pressure ... the same time as well as skill-level adjustable for all ages and abilities. The ...
(Date:1/23/2017)... ... January 23, 2017 , ... Sharon Kleyne, America’s leading ... to educate listeners about the benefits of making new water infrastructure a number one ... “it’s appropriate that we expect water infrastructure to become a top priority of our ...
(Date:1/23/2017)... ... January 23, 2017 , ... Zachary Cattell, President of ... a healthcare industry expert at the 2017 Sector Summit hosted by Ivy Tech ... Business host Gerry Dick, will feature an employer and an association representative from ...
(Date:1/23/2017)... ... January 23, 2017 , ... Moisture measurement ... the right method is paramount to success. Selecting an inappropriate measurement method can ... multiple persons use the same equipment. Rare or expensive substances are wasted and ...
Breaking Medicine News(10 mins):